BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27815457)

  • 1. A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts.
    Caffrey PB; Frenkel GD; McAndrew KL; Marks K
    In Vivo; 2016 11-12; 30(6):745-749. PubMed ID: 27815457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
    Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
    NĂ©mati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
    Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
    Yang X; Tang C; Luo H; Wang H; Zhou X
    Oncotarget; 2017 Apr; 8(14):23664-23674. PubMed ID: 28423588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates.
    Poupon MF; Arvelo F; Goguel AF; Bourgeois Y; Jacrot M; Hanania N; Arriagada R; Le Chevalier T
    J Natl Cancer Inst; 1993 Dec; 85(24):2023-9. PubMed ID: 7902445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of insulin-like growth factor-binding protein 7 in cisplatin-resistant non-small cell lung cancer.
    Okamura J; Huang Y; Moon D; Brait M; Chang X; Kim MS
    Cancer Biol Ther; 2012 Feb; 13(3):148-55. PubMed ID: 22277373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.
    Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M
    Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.
    Heike Y; Takahashi M; Ohira T; Arioka H; Funayama Y; Nishio K; Ogasawara H; Saijo N
    Cancer Chemother Pharmacol; 1995; 35(3):200-4. PubMed ID: 7805177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
    Mueller T; Pfankuchen DB; Wantoch von Rekowski K; Schlesinger M; Reipsch F; Bendas G
    Molecules; 2017 May; 22(5):. PubMed ID: 28467373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
    Li H; Wang H; Deng K; Han W; Hong B; Lin W
    Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
    Shaw GL; Gazdar AF; Phelps R; Steinberg SM; Linnoila RI; Johnson BE; Oie HK; Russell EK; Ghosh BC; Pass HI; Minna JD; Mulshine JL; Ihde DC
    J Cell Biochem Suppl; 1996; 24():173-85. PubMed ID: 8806100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite.
    Caffrey PB; Frenkel GD
    Anticancer Res; 2013 Oct; 33(10):4249-54. PubMed ID: 24122988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
    Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts.
    Arvelo F; Poupon MF; Bichat F; Grossin F; Bourgeois Y; Jacrot M; Bastian G; Le Chevalier T
    Eur J Cancer; 1995 Oct; 31A(11):1862-8. PubMed ID: 8541114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.
    Manzotti C; Pratesi G; Menta E; Di Domenico R; Cavalletti E; Fiebig HH; Kelland LR; Farrell N; Polizzi D; Supino R; Pezzoni G; Zunino F
    Clin Cancer Res; 2000 Jul; 6(7):2626-34. PubMed ID: 10914703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.